3 Cheap Obesity Stocks to Buy ASAP

These stocks offer some of the best opportunities in this market [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Some of the best opportunities can still be found in obesity treatment stocks. --------------------------------------------------------------- Company: Viking Therapeutics (SYM: VKTX) Look at Viking Therapeutics (SYM: VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally back to $70, near-term. All as it nears Phase 3 trials for its obesity treatment, VK2735. In fact, as noted by the company, “We are advancing this compound into Phase 3 development,” CEO Brian Lian said, as noted in a company press release, adding that “we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year.” --------------------------------------------------------------- Weiss Ratings [Nvidia’s Quiet $1 Trillion Pivot]( Nvidia and its powerful chips are the face of artificial intelligence. But while everyone’s patting Nvidia on the back for record earnings… It’s quietly moved on to the next phase of AI it plans to conquer… Nvidia recently unveiled essential blueprints for this crucial $1 trillion pivot. [Click here now and find out about the three companies Nvidia absolutely needs to succeed in this vital new AI frontier.]( --------------------------------------------------------------- Company: Structure Therapeutics (SYM: GPCR) Structure Therapeutics (SYM: GPCR) just announced that its 2b obesity treatment study for GSBR-1290 would start in the fourth quarter of the year. In a prior study, GSBR-1290 “demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks,”according to a company press release. According to JPMorgan, “We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035. GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.” --------------------------------------------------------------- Paradigm Press [Man who Predicted Trump’s Win in 2016 Issues 2024 Prediction]( In 2016, even though surveys were giving Hillary Clinton more than 99% chance of winning right up until election night… Former advisor to the CIA, the Pentagon and the White House Jim Rickards predicted Trump’s win. You won’t believe what he’s predicting now. [Click here to see it because it’s a SHOCKER…]( And it could have huge implications for the financial markets. --------------------------------------------------------------- Company: Altimmune (SYM: ALT) There’s also Altimmune (SYM: ALT), whose pemvidutide treatment led to weight loss while preserving lean mass. That alone set it apart from the competition, with reports that Wegovy and Zepbound can lead to significant loss of muscle mass. As noted in a company press release, “Preservation of lean mass may reduce risk of falls and fractures, development of co-morbidities, and rates of all-cause mortality, particularly in individuals over the age of 60,” said Scott Harris, M.D., Chief Medical Officer. “Our data demonstrates pemvidutide’s class-leading lean mass preservation, superior to that reported historically with diet and exercise.” --------------------------------------------------------------- Marketbeat [The Best 10 AI Stocks to Own in 2024](Discover the AI pioneer 99% of investors have never heard of … but it’s one of my top picks to own now. This company has been an AI pioneer since before anyone ever heard of ChatGPT. Its sustained high double-digit growth has analysts raising price targets. [Get the name—FREE. Discover this under-the-radar AI stock now, ahead of the crowd.]( (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own any obesity-treatment stocks or other biotechs? Do you have your eye on any under-the-radar biotechs you think we should look into? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â